


AMENDMENTS TO THE CLAIMS

1. (previously presented) A compound of formula (I)




or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, wherein:

R^1 and R^2 are each independently hydrogen or methoxy, provided R^1 and R^2 are not both hydrogen or both methoxy;

n is 1, 2, 3, or 4;

X is a bond, O, S, C=O, -N(R)-, wherein R is hydrogen or -(C₁-C₃)alkyl, -C(OH)- or -SO₂; and

Y is benzoxazolyl, benzothiazolyl, benzofurazanyl, benzofuranyl, benzothiadiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, pyridyl, isatinyl, oxindolyl, indazolyl, indolyl, phenyl, thienyl or furanyl; wherein Y is optionally substituted independently with from one to three halogen, trifluoromethyl, methoxy, -C(=O)CH₃, cyano, -C(CH₃)₂OH, -CH(CH₃)OH, -CH(CF₃)OH, -C(C=O)CF₃, -SO₂NH₂, -C(=O)OCH₃, -CH₂COOH, , thiazolyl or oxadiazolyl.

2. (previously presented) The compound of claim 1, wherein X is a bond; and Y is benzofurazanyl, thienyl, pyridyl, or phenyl, wherein said phenyl is optionally substituted independently with one or two halogen, trifluoromethyl, methoxy, -C(=O)CH₃, cyano, -C(CH₃)₂OH, -CH(CH₃)OH, -CH(CF₃)OH, -C(C=O)CF₃, -SO₂NH₂, -C(=O)OCH₃, -CH₂COOH, thiazolyl or oxadiazolyl; or a pharmaceutically acceptable salt thereof.

3. (previously presented) The compound of claim 1, wherein X is a bond; n is 2 or 3; and Y is thienyl, pyridyl or phenyl, wherein said phenyl is optionally substituted independently with

one or two methoxy, halogen, $-\text{C}(\text{CH}_3)_2\text{OH}$, $\text{CH}(\text{CF}_3)\text{OH}$ or $-\text{C}(\text{C}=\text{O})\text{CF}_3$; or a pharmaceutically acceptable salt thereof.

4. (original) N^2, N^4 -bis-(3,5-Dimethoxy-benzyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-pyridin-4-yl-ethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-thiophen-2-yl-ethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -2-phenethyl-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,5-dimethoxy-benzyl)- N^2 -[2-(3,5-dimethoxy-phenyl)-ethyl]-pyrido[2,3-d]pyrimidine-2,4-diamine;
2-(3-{3-[4-(3,4-dimethoxy-benzylamino)-pyrido[2,3-d]pyrimidin-2-ylamino]-propyl}-phenyl)-propan-2-ol;
 N^4 -(3,4-dimethoxy-benzyl)- N^2 -[2-(4-fluoro-phenyl)-ethyl]-pyrido[2,3-d]pyrimidine-2,4-diamine;
 N^4 -(3,4-dimethoxy-benzyl)- N^2 -phenethyl-pyrido[2,3-d]pyrimidine-2,4-diamine; or
 N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

5. (previously presented) A pharmaceutical composition comprising a compound of formula (I) of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

6. (currently amended) A method of treating bone fracture or bone defect, occurring individually or together, or of promoting bone in-growth ~~a PDE 2-mediated condition, disease or symptom~~ in a mammal in need of such treatment which method comprises administering to said mammal a therapeutically effective amount of a compound of formula (I) of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; or a pharmaceutical composition comprising said compound of formula (I), said prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

7. (currently amended) The method of claim 6, wherein ~~said condition, disease or symptom is osteoporosis, pulmonary hypertension, female sexual arousal disorder, diminished memory or cognition, platelet aggregation, vascular angiogenesis, dementia, cancer, arrhythmia, thrombosis, bone fracture, bone defect, bone fracture is treated and bone defect, delayed or non-union fracture, spinal fusion, bone in-growth, cranial facial reconstruction or hypoxia.~~

8. (currently amended) The method of claim 6 7, wherein ~~said condition is bone fracture, bone defect, or bone fracture is delayed or non-union bone fracture and bone defect.~~

9.-11. (canceled)

12. (previously presented) The method of claim 6, further comprising administering to said mammal a therapeutically effective amount of an EP₂ selective receptor agonist; or a prodrug thereof, or a pharmaceutically acceptable salt of said EP₂ selective receptor agonist or prodrug.

13. (previously presented) The method of claim 12, wherein the compound of formula (I) is *N*⁴-(3,5-dimethoxy-benzyl)-*N*²-(2-pyridin-4-yl-ethyl)-pyrido[2,3-d]pyrimidin-2,4-diamine; 2-(3-{3-[4-(3,4-dimethoxy-benzylamino)-pyrido[2,3-d]pyrimidin-2-ylamino]-propyl}-phenyl)-propan-2-ol; *N*⁴-(3,4-dimethoxy-benzyl)-*N*²-(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

14. (previously presented) The method of claim 12, wherein said EP₂ selective receptor agonist is (3-(((4-*tert*-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

15. (canceled)

16. (previously presented) The compound of claim 2, wherein n is 2 or 3; and Y is thienyl, pyridyl or phenyl, wherein said phenyl is optionally substituted independently with one or two methoxy, halogen, -C(CH₃)₂OH, CH(CF₃)OH or -C(C=O)CF₃; or a pharmaceutically acceptable salt thereof.

17. (previously presented) A pharmaceutical composition comprising a compound of claim 4, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

18. (currently amended) A method of treating bone fracture or bone defect, occurring individually or together, or of promoting bone in-growth ~~a PDE-2-mediated condition, disease, or symptom~~ in a mammal in need of such treatment which method comprises administering to said mammal a therapeutically effective amount of a compound claim 4, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; or a pharmaceutical composition comprising said compound claim 4, said prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

19. (canceled)

20. (previously presented) The method of claim 13, wherein said EP₂ selective receptor agonist is (3-(((4-*tert*-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenoxy)-acetic acid, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

21. (previously presented) *N*⁴-(3,4-dimethoxy-benzyl)-*N*²-(3-phenyl-propyl)-pyrido[2,3-*d*]pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt thereof.